Drug Manufacturers - General · NASDAQ
当前价格
$181.55
内在价值
使用下方计算器估算
对 Biogen Inc. 运行 PE 市盈率估值，自动填充盈利数据，可调节目标 PE，即时获得公允价值估算。
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Earnings Yield
4.86%
ROE (TTM)
7.3%
基于过去 12 个月的数据，BIIB 每股收益为 N/A，市盈率为 N/A。 这些是使用 PE 市盈率方法进行股票估值的关键输入。
BIIB 的过去 12 个月市盈率为 可在计算器中查看。该估值指标反映投资者为 Biogen Inc. 每一美元收益所支付的价格。使用 MiniValuator 的 PE 计算器进行详细分析。
BIIB 是否被高估取决于将其市盈率与行业同类公司、历史均值和增长预期进行比较。高于行业平均的市盈率可能表明被高估，但高成长性公司通常有更高的市盈率。在 MiniValuator 上运行完整估值来分析。
使用市盈率对 BIIB 估值：将其当前 PE 与行业平均值比较，分析 PEG 比率进行增长调整估值，查看历史 PE 区间，并通过目标 PE 乘以 EPS 估算公允价值。MiniValuator 的 PE 计算器可自动完成此分析。
BIIB 的 PEG 比率为 可在计算器中查看。PEG 比率将市盈率除以盈利增长率——PEG 低于 1.0 可能表明股票相对于其增长被低估，是一个有用的辅助估值指标。
PE 市盈率提供快速的相对估值——BIIB 与同类公司的比较。DCF 提供绝对估值——基于预期现金流的股票内在价值。建议同时使用两种方法进行综合估值。MiniValuator 同时提供 PE 和 DCF 计算器。
